[{"id":"914653e2-dfa1-47cf-b128-9f2a0b04b4a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01075308","created_at":"2021-01-18T04:14:13.456Z","updated_at":"2024-07-02T16:35:41.030Z","phase":"Phase 2","brief_title":"SB939 in Treating Patients With Recurrent or Metastatic Prostate Cancer","source_id_and_acronym":"NCT01075308","lead_sponsor":"NCIC Clinical Trials Group","biomarkers":" PTEN • ERG • TMPRSS2","pipe":" | ","alterations":" PTEN deletion • TMPRSS2-ERG fusion","tags":["PTEN • ERG • TMPRSS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN deletion • TMPRSS2-ERG fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pracinostat (SB939)"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 06/28/2010","start_date":" 06/28/2010","primary_txt":" Primary completion: 01/05/2015","primary_completion_date":" 01/05/2015","study_txt":" Completion: 02/13/2015","study_completion_date":" 02/13/2015","last_update_posted":"2023-08-04"},{"id":"59ce81d4-311d-4568-926a-4dc4082edb0d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03848754","created_at":"2021-01-18T18:59:49.571Z","updated_at":"2024-07-02T16:36:08.074Z","phase":"Phase 1","brief_title":"Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT03848754","lead_sponsor":"Medical College of Wisconsin","biomarkers":" CD33","pipe":" | ","alterations":" CD33 expression","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin) • pracinostat (SB939)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 05/24/2019","start_date":" 05/24/2019","primary_txt":" Primary completion: 05/05/2021","primary_completion_date":" 05/05/2021","study_txt":" Completion: 05/05/2021","study_completion_date":" 05/05/2021","last_update_posted":"2022-06-30"}]